- Corticosteroid-responsive conditions:
- IM 60mg *1
- Range: 40-80mg *1
- Allergic conditions:
- IM 40-100mg *1
- IM 40-100mg *1
- Acute exacerbation of multiple sclerosis:
- IM 160mg OD *1/52, then IM 64mg OD *1/12
- IM 160mg OD *1/52, then IM 64mg OD *1/12
- Acute gout:
- Small joints: 5-5mg intra-articularly *1
- Max: 10mg/site up to 80mg/total dose
- Max: 10mg/site up to 80mg/total dose
- Small joints: 5-5mg intra-articularly *1
- Large joints: 5-15mg intra-articularly *1
- Max: 40mg/site up to 80mg/total dose
- Rheumatoid arthritis or osteoarthritis:
- Small joints: 5-5mg intra-articularly *1
- Max: 10mg/site up to 80mg/total dose
- Max: 10mg/site up to 80mg/total dose
- Small joints: 5-5mg intra-articularly *1
-
- Large joints: 5-15mg intra-articularly *1
- Max: 40mg/site up to 80mg/total dose
- Max: 40mg/site up to 80mg/total dose
- Large joints: 5-15mg intra-articularly *1
- Steroid-responsive dermatoses:
- Intralesional injection: 1mg per injection site 1 or more times weekly
- Max 30mg/day
- Max 30mg/day
- Intralesional injection: 1mg per injection site 1 or more times weekly
- Joint and joint structure inflammation:
- Small joints: 5-5mg intra-articularly *1
- Max: 10mg/site up to 80mg/total dose
- Max: 10mg/site up to 80mg/total dose
- Small joints: 5-5mg intra-articularly *1
-
- Large joints: 5-15mg intra-articularly *1
- Max: 40mg/site up to 80mg/total dose
- Large joints: 5-15mg intra-articularly *1
Injection: 40mg
- With intra-articular administration, use a local anesthetic prior
- When administered intralesionally, inject directly into the lesion
Corticosteroid
It inhibits multiple inflammatory cytokines, producing multiple glucocorticoid and mineralocorticoid effects
- Joint swelling
- Post-injection flare (intra-articular use)
- Cushingoid appearance
- Hirsutism
- Weight gain
- Erythema
- Abdominal discomfort
- Appetite changes
- Emotional lability
- Rash
- Urticaria
- Nausea
- Vomiting
- Sodium retention
- Fluid retention
- Hypokalemia
- Elevated BP
- Edema
- Diaphoresis
- Muscle atrophy
- Impaired wound healing (long-term use)
- Skin atrophy (long-term use)
- Petechiae
- Ecchymosis
- Skin pigmentation abnormality
- Acne
- Headache
- Dizziness
- Vertigo
- Insomnia
- Depression
- Anxiety
- Glucose intolerance
- Cushing syndrome (long-term use)
- Menstrual irregularities
- Increased IOP
- Hypersensitivity to class/components
- IV use
- Intrathecal, intraocular or intradermal use
- Epidural use
- Neonates
- Premature infants
- Thrombocytopenic purpura (IM use)
- Systemic fungal infection
- Cerebral malaria
- Latent or active amebiasis
- Unstable joint (intra-articular use)
- Joint infection or history (intra-articular use)
- Traumatic brain injury (high-dose use)
- Abrupt withdrawal (high-dose or long-term use)
- Live bacterial vaccines
- Desmopressin
- Mifepristone
- Tamoligene
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Weigh risk vs benefit |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Cenolon | 40mg | Injection | 1’s | Radiance Pharma | Radiance Pharma |
Kenalog | 40mg | Injection | 5’s | Bristol-Myers Squibb | Bristol-Myers Squibb |
Triam-Denk | 40mg | Injection | 10’s | Denk Pharma | Laborex Kenya |
Trinocort | 40mg | Injection | 1’s | Asence Pharma | Medisel Kenya |